샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737324

세계의 PD-1 및 PD-L1 억제제 시장

PD-1 and PD-L1 Inhibitors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 376 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

PD-1 및 PD-L1 억제제 세계 시장은 2030년까지 1,428억 달러에 달할 전망

2024년에 509억 달러로 추정되는 PD-1 및 PD-L1 억제제 세계 시장은 2024-2030년 분석 기간 동안 CAGR 18.7%로 성장하여 2030년에는 1,428억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 PD-1 억제제는 CAGR 20.4%를 기록하며 분석 기간 종료시에는 1,011억 달러에 달할 것으로 예측됩니다. PD-L1 억제제 부문의 성장률은 분석 기간 동안 CAGR 15.3%로 추정됩니다.

미국 시장은 139억 달러로 추정, 중국은 CAGR 24.9%로 성장할 것으로 예측

미국의 PD-1 및 PD-L1 억제제 시장은 2024년에 139억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 325억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 24.9%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 각각 분석 기간 동안에 13.8%와 17.0%의 CAGR로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 15.0%로 성장할 것으로 예측됩니다.

세계의 PD-1 및 PD-L1 억제제 시장 - 주요 동향과 촉진요인 정리

PD-1 및 PD-L1 억제제가 여러 암종에 대한 면역치료에 혁명을 일으키고 있는 이유는 무엇일까?

프로그램된 세포사멸 단백질-1(PD-1)과 그 리간드인 PD-L1 억제제는 면역체계가 종양세포를 인식하고 공격할 수 있도록함으로써 종양학을 근본적으로 변화시켰습니다. 이러한 체크포인트 억제제는 PD-1/PD-L1 경로를 파괴하고, 암세포가 면역 탐지를 피하기 위해 사용하는 PD-1/PD-L1 경로를 파괴하여 T세포의 활성을 회복하고 지속적인 항종양 반응을 촉진합니다. 초기에는 전이성 흑색종, 비소세포폐암(NSCLC), 신세포암으로 승인되었으나 현재는 삼중음성유방암, 간세포암, 요로상피암, 두경부암 등 다양한 암에 대해 연구 및 승인되었습니다.

이 계열의 면역항암제는 진행성 암이나 난치성 암에서도 장기간 효과가 지속되는 것으로 알려져 있습니다. 펨브롤리주맙(키트루다), 니볼루맙(옵디보), 아테졸리주맙(테센트릭), 둘발루맙(임핀지)과 같은 약제들은 종종 1차 또는 유지요법으로 암 치료 요법의 중요한 축을 이루고 있으며, PD-1/PD-L1 억제제는 현재 화학요법, 표적 치료제, 방사선요법, 신보조요법, 표적 치료제, 방사선치료와 함께 방사선 치료와 병행하여 신보조요법, 보조요법, 병용요법으로 시험되고 있으며, 암의 병기 및 치료 라인을 넘어 그 적용 범위가 확대되고 있습니다.

바이오마커 기반 접근법과 병용요법은 PD-1/PD-L1 저해의 미래를 어떻게 형성할 것인가?

PD-1 및 PD-L1 치료의 성공을 위해 PD-L1 발현 수준, 종양 돌연변이 부하(TMB), 미세위성 불안정성(MSI), 종양침윤림프구(TIL)의 존재 여부는 PD-L1 반응자를 식별하고 치료 요법을 개별화하기 위해 사용되어 왔습니다. IHC 분석 및 차세대 염기서열 분석(NGS)을 포함한 동반진단법은 현재 임상적 의사결정에 통합되어 효능을 최적화하고 면역 관련 이상반응(irAE)을 최소화하기 위해 사용되고 있습니다.

PD-1/PD-L1 억제제와 CTLA-4 억제제(예 : 이필리무맙), VEGF 억제제(예 : 베바시주맙), 저분자 TKI와 PD-1/PD-L1 억제제의 병용요법 시험에서 시너지 효과가 입증되었습니다. 암 백신, CAR-T 요법, 마이크로바이옴 조절, 온콜루시스 바이러스를 포함한 새로운 접근법은 내성을 극복하고 효능을 확대하기 위해 평가되고 있습니다. 이러한 멀티모달 접근법은 고형암과 혈액암 모두에서 PD-1/PD-L1 저해의 환자 수와 치료 효과를 크게 확대할 수 있을 것으로 기대됩니다.

PD-1/PD-L1 억제제 수요를 주도하는 적응증 및 지역 시장은?

비소세포폐암은 여전히 가장 큰 적응증으로, 높은 유병률과 잘 확립된 바이오마커 프레임워크로 인해 면역항암제 매출의 큰 비중을 차지하고 있습니다. 흑색종, 신세포암, 두경부 편평상피암도 주요 치료 영역입니다. 자궁내막암, 위암, 식도암, 방광암에서 새로운 승인을 받고 있으며, 교모세포종, 난소암, 대장암에서 진행 중인 임상시험이 추가 승인을 받을 것으로 예상됩니다.

북미는 조기 승인, 유리한 상환 정책, 강력한 임상시험 인프라에 힘입어 시장 수익을 독식하고 있습니다. 유럽이 그 뒤를 이어 EMA와 각국 보건당국의 승인을 받고 있습니다. 아시아태평양은 빠르게 성장하고 있는 지역으로, 특히 중국과 일본에서는 국내 기업들이 바이오시밀러 및 신규 체크포인트 억제제 개발을 진행하고 있습니다. 암 면역요법에 대한 규제 당국의 빠른 승인과 정부의 투자가 활발한 경쟁에 기여하고 있습니다. 중동과 라틴아메리카에서는 암 연구 보조금 프로그램 및 다국적 기업과의 제휴를 통해 점차 접근성이 확대되고 있습니다.

PD-1/PD-L1 억제제 시장의 장기적인 성장과 전략적 혁신의 원동력은?

PD-1/PD-L1 억제제 시장 성장의 원동력은 암 발병률 증가, 적응증 확대, 병용요법 및 차세대 면역치료제의 탄탄한 임상 파이프라인입니다. 면역종양학이 암 치료의 중심이 되면서 대형 제약사, 바이오테크 스타트업, 학계의 투자가 새로운 적응증, 예측 바이오마커, 내성 메커니즘에 대한 연구에 박차를 가하고 있습니다. 유전체학, 리얼월드 증거, AI 기반 시험 설계의 융합은 혁신과 시장 진입 전략을 가속화하고 있습니다.

전략적으로, 기업들은 새로운 제형(피하주사), 초기 치료제로의 확장, 바이오마커에 연동된 가격 책정 모델을 통한 라이프사이클 관리에 초점을 맞추고 있습니다. 전략적 제휴, 라이선스 계약, 세계 공동 상업화 계약은 시장 역학을 재구성하고 있으며, PD-1/PD-L1 바이오시밀러와 비용 효율적인 체크포인트 치료제의 개발은 가격에 민감한 시장에서 접근성을 향상시킬 것으로 예상됩니다. 면역치료가 고형암과 혈액암의 주요 치료제로 자리 잡으면서 PD-1/PD-L1 억제제는 과학적 혁신, 임상적 유용성, 세계 건강 영향의 융합을 통해 종양학 혁신의 최전선에 계속 서게 될 것입니다.

부문

억제제 종류(PD-1 억제제, PD-L1 억제제), 암 종류(신장암, 흑색종, 방광암, 비소세포폐암, 간암, 두경부암, 기타 암), 판매 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 34개사)

  • AbbVie Inc.
  • Akeso Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Takeda Pharmaceutical Company Limited

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global PD-1 and PD-L1 Inhibitors Market to Reach US$142.8 Billion by 2030

The global market for PD-1 and PD-L1 Inhibitors estimated at US$50.9 Billion in the year 2024, is expected to reach US$142.8 Billion by 2030, growing at a CAGR of 18.7% over the analysis period 2024-2030. PD-1 Inhibitors, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$101.1 Billion by the end of the analysis period. Growth in the PD-L1 Inhibitors segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.9 Billion While China is Forecast to Grow at 24.9% CAGR

The PD-1 and PD-L1 Inhibitors market in the U.S. is estimated at US$13.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.5 Billion by the year 2030 trailing a CAGR of 24.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.8% and 17.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.0% CAGR.

Global PD-1 and PD-L1 Inhibitors Market - Key Trends & Drivers Summarized

Why Are PD-1 and PD-L1 Inhibitors Revolutionizing Immunotherapy Across Multiple Cancer Types?

Programmed cell death protein-1 (PD-1) and its ligand PD-L1 inhibitors have fundamentally transformed oncology by enabling the immune system to recognize and attack tumor cells. These checkpoint inhibitors disrupt the PD-1/PD-L1 pathway-used by cancer cells to evade immune detection-restoring T-cell activity and facilitating a durable anti-tumor response. Initially approved for metastatic melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, PD-1 and PD-L1 inhibitors are now being investigated and approved for a wide array of cancers, including triple-negative breast cancer, hepatocellular carcinoma, urothelial carcinoma, and head and neck cancers.

This class of immunotherapy is favored for its ability to produce long-lasting responses, even in advanced or refractory cancers. Drugs such as pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq), and durvalumab (Imfinzi) have become key pillars in oncology regimens, often as first-line or maintenance therapies. PD-1/PD-L1 inhibitors are now being trialed in neoadjuvant, adjuvant, and combination settings alongside chemotherapy, targeted therapy, and radiation, expanding their application across cancer stages and treatment lines.

How Are Biomarker-Driven Approaches and Combination Therapies Shaping the Future of PD-1/PD-L1 Inhibition?

Biomarker-driven patient selection is becoming central to the success of PD-1 and PD-L1 therapies. Expression levels of PD-L1, tumor mutation burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating lymphocytes (TILs) are being used to identify responders and personalize treatment regimens. Companion diagnostics, including IHC assays and next-generation sequencing (NGS), are now integrated into clinical decision-making to optimize efficacy and minimize immune-related adverse events (irAEs).

Combination strategies are the most promising frontier in this class. Trials combining PD-1/PD-L1 inhibitors with CTLA-4 blockers (e.g., ipilimumab), VEGF inhibitors (e.g., bevacizumab), and small molecule TKIs are showing synergistic effects. Novel approaches involving cancer vaccines, CAR-T therapy, microbiome modulation, and oncolytic viruses are being evaluated to overcome resistance and broaden efficacy. These multi-modal approaches are expected to significantly expand the patient pool and therapeutic benefit of PD-1/PD-L1 inhibition in both solid tumors and hematologic malignancies.

Which Indications and Regional Markets Are Driving Demand for PD-1 and PD-L1 Inhibitor Therapies?

Non-small cell lung cancer remains the largest indication for PD-1 and PD-L1 inhibitors, accounting for a significant share of immuno-oncology sales due to its high prevalence and well-established biomarker frameworks. Melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma also constitute major treatment areas. Emerging approvals in endometrial, gastric, esophageal, and bladder cancers are expanding market scope, with ongoing trials in glioblastoma, ovarian, and colorectal cancers expected to yield additional approvals.

North America dominates market revenue, driven by early approvals, favorable reimbursement policies, and strong clinical trial infrastructure. Europe follows, with increasing uptake through the EMA and national health authorities. Asia-Pacific is the fastest-growing region, particularly in China and Japan, where domestic companies are developing biosimilars and novel checkpoint inhibitors. Rapid regulatory approvals and government investments in cancer immunotherapy are contributing to a vibrant, competitive landscape. The Middle East and Latin America are gradually expanding access via oncology funding programs and multinational partnerships.

What Is Driving Long-Term Growth and Strategic Innovation in the PD-1/PD-L1 Inhibitors Market?

The growth in the PD-1 and PD-L1 inhibitors market is driven by increasing cancer incidence, broader label expansions, and the robust clinical pipeline of combination and next-generation immunotherapies. As immuno-oncology becomes central to cancer care pathways, investment from Big Pharma, biotech startups, and academic institutions is fueling research into new indications, predictive biomarkers, and resistance mechanisms. The convergence of genomics, real-world evidence, and AI-based trial design is accelerating innovation and market access strategies.

Strategically, companies are focusing on lifecycle management through new dosage forms (subcutaneous injections), expansion into earlier treatment lines, and biomarker-linked pricing models. Strategic alliances, licensing deals, and global co-commercialization agreements are reshaping market dynamics. The development of PD-1/PD-L1 biosimilars and cost-effective checkpoint alternatives is expected to improve access in price-sensitive markets. As immunotherapy becomes a mainstay across solid tumors and hematologic malignancies, PD-1/PD-L1 inhibitors will remain at the forefront of oncologic innovation, driven by a blend of scientific breakthroughs, clinical utility, and global health impact.

SCOPE OF STUDY:

The report analyzes the PD-1 and PD-L1 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type of Inhibitor (PD-1 Inhibitors, PD-L1 Inhibitors); Cancer Type (Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck, Other Cancer Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Akeso Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • BeiGene, Ltd.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • PD-1 and PD-L1 Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Burden Propels Demand for Immuno-Oncology Agents Targeting PD-1 and PD-L1
    • Expansion of Indications Beyond Melanoma and NSCLC Drives Market Diversification for Checkpoint Inhibitors
    • Breakthrough Approvals and Accelerated Review Pathways Throw the Spotlight on PD-1/PD-L1 Drug Pipelines
    • Growing Investment in Combination Therapies Strengthens Business Case for Synergistic Cancer Treatment
    • Emergence of Biomarker-Driven Patient Selection Enhances Clinical Outcomes and Cost-Effectiveness
    • Rapid Expansion of Clinical Trials in Rare and Hard-to-Treat Cancers Supports Label Expansion
    • Adoption of Companion Diagnostics and Tumor Profiling Supports Personalized Immunotherapy Protocols
    • Rising Emphasis on Real-World Evidence Collection Enhances Market Access and Payer Negotiations
    • Availability of Subcutaneous and Long-Acting Formulations Drives Patient Convenience and Compliance
    • Integration of Artificial Intelligence in Trial Design Accelerates Immunotherapy Development Pipelines
    • Collaborations Between Pharma and Academic Institutions Fuel Discovery of Novel Checkpoint Targets
    • Price Competition From Biosimilars and Global Reference Products Spurs Cost Optimization Strategies
    • Growth in Neoantigen Vaccine Research Creates Synergies With PD-1/PD-L1 Blockade Therapies
    • Use of PD-1/PD-L1 Inhibitors in Neoadjuvant and Adjuvant Settings Expands Clinical Application Scope
    • Regulatory Support for Tumor-Agnostic Therapies Strengthens Positioning in Precision Oncology
    • Development of Next-Generation Checkpoint Modulators Enhances Efficacy in Resistant Patient Populations
    • Increased Reimbursement in Developed Markets Encourages Broader Adoption Across Oncology Centers
    • Challenges in Immune-Related Adverse Events Drive Development of Predictive Risk Models
    • Global Disparities in Access to Immunotherapy Highlight Opportunities for Tiered Pricing and Localization
    • Strategic Licensing and Co-Development Agreements Accelerate Commercial Footprint in Competitive Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PD-1 and PD-L1 Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for PD-1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for PD-1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for PD-1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Bladder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Bladder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Non-small Cell Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Non-small Cell Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Non-small Cell Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Head & Neck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Head & Neck by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Head & Neck by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • JAPAN
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • CHINA
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • EUROPE
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • FRANCE
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • GERMANY
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • INDIA
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030
  • AFRICA
    • PD-1 and PD-L1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - PD-1 Inhibitors and PD-L1 Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Type of Inhibitor - Percentage Breakdown of Value Sales for PD-1 Inhibitors and PD-L1 Inhibitors for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for PD-1 and PD-L1 Inhibitors by Cancer Type - Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for PD-1 and PD-L1 Inhibitors by Cancer Type - Percentage Breakdown of Value Sales for Kidney, Melanoma, Bladder, Non-small Cell Lung Cancer, Liver, Head & Neck and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제